1,034 results on '"Strober, Bruce"'
Search Results
102. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from adalimumab, ustekinumab, or secukinumab: Results from phase 3/3b trials
103. Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
104. Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
105. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2
106. Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials
107. Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension
108. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials
109. Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
110. Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
111. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial
112. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting
113. 34321 Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
114. 33064 Correlation of fatigue severity and psoriasis severity, and the treatment effect of guselkumab: A detailed analysis of SF-36 vitality scores from the VOYAGE 2 study
115. 33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study
116. 33120 Early and sustained improvement in atopic dermatitis (AD) disease control and treatment satisfaction with dupilumab in clinical practice: Long-term data from the RELIEVE-AD study
117. 33817 Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
118. 34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
119. 33325 Long-term dupilumab effectiveness on health-related quality of life (HRQoL) and work productivity in atopic dermatitis (AD): Results from RELIEVE-AD
120. 33933 Relationship between skin involvement and disease burden in patients with mild to moderate plaque psoriasis: Real-world findings From CorEvitas’ Psoriasis Registry
121. 32432 Significant nail improvement occurs as early as 24 weeks and lasts long-term through 5 years in ixekizumab treated patients with moderate-to-severe psoriasis and significant nail involvement
122. 35205 Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials
123. 34940 Real-world patient-reported outcomes with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
124. 51212 The Registry of Psoriasis Health Outcomes (RePhlect): Characteristics of Early Adopters of Deucravacitinib in the North American Region
125. 51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per Dermatology Life Quality Index scores: Data from the Effisayil 2 trial
126. 50876 Real-world Treatment Patterns in Patients with Generalized Pustular Psoriasis: Results from a US Claims Analysis
127. 51099 Real-world application of the International Psoriasis Council guidelines for prescribing systemic treatment to patients with psoriasis in North America
128. 52284 Influence of Biological Sex on Clinical Manifestation in Moderate-to-Severe Atopic Dermatitis and on Dupilumab Treatment Effectiveness
129. 52842 Dupilumab Improves Health-Related Quality of Life and Work Productivity Among Adults With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 4-Year Follow-up Results From the RELIEVE-AD Study
130. 54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
131. 52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
132. 52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
133. 50857 Treatment Discontinuation Patterns in Patients With Psoriasis Receiving Apremilast in North America: A Registry-Based Analysis
134. 51349 Spesolimab for the prevention of generalized pustular psoriasis (GPP) flares in White/Caucasian patients: Results from the randomized, placebo-controlled Effisayil 2 study
135. 54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
136. 50668 Long-term Impact of Apremilast on Cardiometabolic Parameters and the Relationship of Cardiometabolic Changes With Psoriasis Efficacy
137. 51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry
138. 52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA
139. 51342 Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the Effisayil 2 and Effisayil ON trials
140. 54001 Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks: Subgroup Analysis by Baseline Demographics and Disease Characteristics From the LIMMitless Trial
141. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
142. Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry: A new collaborative approach for postapproval registries
143. Janus Kinase Inhibitors
144. Current biologic therapies (including IL-17) and monitoring guidelines
145. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
146. Item-Level Psychometric Properties for a New Patient-Reported Psoriasis Symptom Diary
147. Upadacitinib for the treatment of psoriasiform and spongiotic dermatitis: A multicenter case series
148. How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials
149. Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry.
150. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.